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Background: The development of a more refined prognostic methodology for early non-small cell lung cancer
(NSCLC) is an unmet clinical need. An accurate prognostic tool might help to select patients at early stages for
adjuvant therapies.
Results: A new integrated bioinformatics searching strategy, that combines gene copy number alterations and
expression, together with clinical parameters was applied to derive two prognostic genomic signatures. The proposed
methodology combines data from patients with and without clinical data with a priori information on the ability of a
gene to be a prognostic marker. Two initial candidate sets of 513 and 150 genes for lung adenocarcinoma (ADC) and
squamous cell carcinoma (SCC), respectively, were generated by identifying genes which have both: a) significant
correlation between copy number and gene expression, and b) significant prognostic value at the gene expression
level in external databases. From these candidates, two panels of 7 (ADC) and 5 (SCC) genes were further identified via
semi-supervised learning. These panels, together with clinical data (stage, age and sex), were used to construct the
ADC and SCC hazard scores combining clinical and genomic data. The signatures were validated in two independent
datasets (n = 73 for ADC, n = 97 for SCC), confirming that the prognostic value of both clinical-genomic models is
robust, statistically significant (P = 0.008 for ADC and P = 0.019 for SCC) and outperforms both the clinical
models (P = 0.060 for ADC and P = 0.121 for SCC) and the genomic models applied separately (P = 0.350 for ADC
and P = 0.269 for SCC).
Conclusion: The present work provides a methodology to generate a robust signature using copy number data that
can be potentially used to any cancer. Using it, we found new prognostic scores based on tumor DNA that, jointly with
clinical information, are able to predict overall survival (OS) in patients with early-stage ADC and SCC.
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Pulmonary resection is the standard treatment for early
stage non-small cell lung cancer (NSCLC). The potential
benefits of adjuvant chemotherapy (ACT) and/or radio-
therapy after surgery have been explored in a large
number of clinical trials [1]. After the publication of two
meta-analyses that showed a significant 5-year survival
improvement of 4 % in patients treated with ACT [2],
guidelines from European and American medical societies
recommend cisplatinum based ACT in stage II-IIIA
patients. Controversial results were obtained in relation to
stage IB patients, which show a slight but statistically non-
significant improvement in overall survival (OS) after
ACT [3]. Adjuvant treatment is not recommended in
stage IA patients because clinical trials showed no bene-
fits, and even a decrease in OS after this treatment.
Despite the progress in therapy in NSCLC, five-year OS
rates are around 65 % for stage I and 40 % for stage II [4].
This is partly due to the fact that the current staging sys-
tem is not precise enough to stratify the real risk of relapse
in early patients. Hence, the discovery and validation of
new molecular biomarkers that could classify these early
patients in subgroups, to identify those with worse prog-
nosis who could benefit from ACT, is a clear unmet need.
A large number of studies have been developed to
define a prognostic genomic signature in early stage lung
cancer, most of them based on mRNA expression micro-
arrays [5–7]. However, although clinical parameters are
validated predictors for OS, most prognostic profiles do
not provide a decision making algorithm combining
both the molecular markers and the clinicopathologic
features (sex, age, stage, etc.) of each patient.
NSCLC can be divided into three main subclasses:
adenocarcinoma (ADC), squamous cell carcinoma (SCC)
and large cell carcinoma (LCC); the most common
subtypes being ADC and SCC. The need of a robust and
reproducible genetic profile is especially apparent for
SCC, as most of the genetic prognostic profiles described
so far for lung cancer patients are restricted to ADC hist-
ology [8]. Indeed, the two commercially available prognos-
tic tests for lung cancer (both RNA-based) are intended
for ADC patients and are not valid for SCC [5, 7]. Despite
the efforts to characterize prognosis of SCC patients
[9–11], the published information has not been trans-
lated into a validated clinically useful tool, partly due
to the existence of several biological subtypes within
the squamous lung tumors [12, 13].
Most of the published prognostic signatures are gene
expression (RNA)-based profiles. Considering the super-
ior stability of DNA compared to RNA, a prognostic
profile based on the analysis of tumor DNA rather than
RNA would most likely achieve a more robust and
reproducible clinical applicability due to the higher sta-
bility of the DNA. Even though some publications havedescribed copy number aberrations (CNA) as predictors
of early stage lung cancer survival, most of them only
focus on individual gene or chromosomic region alter-
ations and do not provide a proposal for a signature based
on CNA in the context of stage I-II lung cancer [14, 15].
The goal of this study was the generation of two new
CNA-based prognostic clinical-genomic signatures for
the prognosis of stage I-II separately for ADC and SCC.
Data from a total of 632 patients were used. We first
analyzed CNA profiles of tumor samples from an initial
cohort of 155 (99 ADC and 56 SCC) stage I-II patients
from three different datasets. Other series of patients
were used to provide additional information to the ana-
lysis and for independent validation. First, we identified
a subset of candidate genes which fulfilled a double
condition: a) positive correlation between copy number
and gene expression; and b) correlative association of
the expression of the gene with prognostic value accord-
ing to two publicly available databases. Next, using the
CNA for each of the selected genes and the clinical data
(if available), we developed the clinical-genomic signa-
ture which estimated an individual patient prognosis.
Finally, both (ADC and SCC) integrative clinical-genomic
signatures were validated using independent series of early
stage, non-treated ADC and SCC patients from The
Cancer Genome Atlas (TCGA) consortium.
In summary, we describe here a new methodology to
derive CNA-based prognostic clinical-genomic signa-
tures and propose two signatures which may be useful in
predicting prognosis of stage I-II ADC and SCC. In our
analysis we also show the strength of combining both
genetic and clinical data in prognostic studies.
Methods
Patients
In the training series, we included clinical-genomic data of
632 patients from 5 different datasets: three previously
published, GSE28582 [16], GSE25016 [17] and GSE34140
[18], and two unpublished, CIMA-CUN-HUMV and The
University of Texas MD Anderson (MDA) Cancer Center.
Patients included in these novel datasets gave the required
informed consent. All patients underwent surgical resec-
tion of NSCLC. Among the 632 specimens included in the
datasets, 338 were ADC (99 labeled and 239 unlabeled
data) and 294 were SCC (56 labeled and 238 unlabeled
data). We considered a sample to be labeled if survival
data were available. All labeled patients had early-stage
tumors (stage IA, IB, IIA or IIB) and did not receive pre-
operative or postoperative chemotherapy. We used the
unlabeled data (from datasets GSE25016 and GSE34140)
as an additional source of information to derive the
clinical-genomic models. The median follow up times for
ADC and SCC training sets were 61 and 73 months,
respectively (Data gathering in Additional file 1). The
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the University of Navarra on April 22nd 2010, approval
ref number 068/2010 and by the MD Anderson Cancer
Center Institutional Review Board 1, on December 7th
2013, Protocol number PA13-0230”.
The clinical-genomic signatures for ADC and SCC
were validated using two independent datasets obtained
from The Cancer Genome Atlas (TCGA; https://
tcga-data.nci.nih.gov/tcga/). These datasets corre-
sponded to patients with completely resected stage I
or II NSCLC who had not received any type of adjuvant
therapy (n = 73 for ADC, and n = 97 for SCC). The median
follow up times for these ADC and SCC validation series
were 20 and 23 months, respectively (Data gathering in
Additional file 1).
Data processing pipeline
Tumor DNA from CIMA-CUN-HUMV DNA samples
was hybridized to Affymetrix 500 K SNP microarrays.
Intensities of scanned images were quantified, normal-
ized and summarized using ACNE [19]. Then, total copy
number values were estimated using NSA [20]. Since
copy number profiling can be affected by stromal con-
tamination, copy number values for each sample were
re-scaled according to their tumor purity using GPHMM
[21] (Core algorithm in Additional file 1). This correc-
tion also reduces variation among samples both within
the same dataset, and across datasets. Next, values were
segmented using CBS [22] to get regions of constantFig. 1 Panel 1, Main processing pipeline steps. Panel 2, Model selection
*Gene Expression (GE). **Databases (DDBB)number of copies. These steps were performed for all
datasets, except for TCGA and MDA datasets. For these
ones, data were already processed by the providers and
the tumor purity values were available, allowing us to
perform the correction. Finally, segmented copy number
values were assigned to each gene. If copy number
changes were found within a gene, a weighted median of
the copy number values of its internal segments was
assigned (Core algorithm in Additional file 1). For some
of the genes, we validated the microarray data using this
pipeline by FISH. We found a high coherence between
both techniques (data not shown). In Fig. 1, panel 1
illustrates the data processing steps described above.
These data have been deposited at the GEO database
(http://www.ncbi.nlm.nih.gov/geo/) in a superseries with
access numbers GSE72195 (it embraces GSE72192 and
GSE72194).
Model selection pipeline
Due to the biological differences between ADC and SCC,
data were analyzed separately. Prior to any analysis, two
filters were applied to generate a list of candidate genes.
Firstly, a “correlation filter” was used to remove those
genes whose copy numbers do not correlate with their
expression. Datasets described above, and data available
from two additional sets of patients [23, 24] were used for
this correlation study. The threshold used to call for a
positive correlation was a local FDR adjusted q-value
smaller than 0.2. Secondly, a “prognostic filter” was usedpipeline followed to obtain the final clinical-genomic signatures.
Aramburu et al. BMC Genomics  (2015) 16:752 Page 4 of 10to remove genes not related to OS based on two external
databases: GeneSigDB [25] and Prognoscan [26]. The list
downloaded from GeneSigDB contained manually curated
genes associated with lung cancer OS (Core algorithm in
Additional file 1). To generate the list from Prognoscan,
we performed a meta-analysis for each gene across all the
available studies included in this database (Core algorithm
in Additional file 1). The selected genes for the prognostic
filter were those that appeared to be significant in any of
the two databases. Our list of candidate genes was thus
prepared looking for those genes which shared both posi-
tive correlation between copy number and gene expres-
sion, and presence in any of the lists of genes with
prognostic value from GeneSigDB or Prognoscan. GO
pathway analyses of the candidate genes were done for
ADC and SCC separately using GeneCoDis software ana-
lysis (http://genecodis.cnb.csic.es).
Next, we used a Cox proportional-hazards regression
analysis to relate survival with clinical data and CNA for
each candidate gene independently using only the training
set. The statistical significance of the coefficient associated
with the analyzed gene determined the gain in classifica-
tion power of the survival model compared with the
clinical model alone. Only clinical data that have proved
to have prognostic value (age, sex and stage) were in-
cluded. Age was considered to be a continuous variable,
sex a dichotomous categorical variable (female was taken
as reference), and stage a categorical variable with ordered
levels (stages). For the latter, the stages were modeled as
incremental risk and stage IA was taken as reference. The
absolute hazard ratio for a given stage in our model was
obtained by summing up the incremental hazard ratios
from earlier stages. In the generation of the survival
models, the Cox coefficients associated with age, sex and
the incremental risks of the stages were forced to be non-
negative. These non-negativity constraints are coherent
with previous clinical studies [4].
To select the most relevant genes for OS prediction,
additional information retrieved from the unlabeled
datasets was incorporated into the model using the
NetRank algorithm [27]. The NetRank algorithm mimics
the PageRank algorithm that Google uses to rank its
results. Each gene has a relevance given by its p-value.
Using a network generated with correlations (using
unlabeled samples), the initial ranking of the p-values
was changed to accommodate the additional information
of the network. With the aid of the Akaike Information
Criterion (AIC), the algorithm selected an ensemble
model that combines the best candidate models (Core
algorithm in Additional file 1).
Finally, we generated two mathematical models that
predict OS for ADC or SCC. In both models, clinical
(age, sex and stage) and gene copy number data were
included. Then, patients’ risk scores were calculated andpatients were classified as having a high-risk signature or
a low-risk signature with the median of the risk scores as
threshold value. In Fig. 1, panel 2 illustrates the survival
model selection pipeline described above.
Prognostic evaluation
The risk model was validated on the TCGA dataset (that
was not used in the training phase). Using the predicted
risk score, the prediction performance was analyzed with
a univariate Cox proportional hazards regression taking
the corresponding predicted risk scores as explanatory
variable. A one-tailed p-value for a hazard ratio less than
0.05 was considered to be significant. Alternatively, all
patients in the TCGA dataset were dichotomized into
two groups: low-risk and high-risk; and a log-rank test
was also performed. The latter is a non-parametric test
that evaluates the null-hypothesis that both groups have
similar survival. In addition, to carry out a statistical
comparison of the prognostic power of the clinical-
genomic signatures with the prognostic power of mere
clinical signatures, a Harrell’s test was performed [28].
This test compares prediction models and provides
information on whether the alternative model is signifi-
cantly better than the reference model. In our case, we
performed two different Harrell’s tests for both ADC
and SCC. In the first test, we compared the clinical-
genomic test with a reference model that included only
clinical variables. In the second, we compared the gen-
etic test with the clinical-genomic one.
Results
Using lung ADC and SCC data from three labeled and
two unlabeled datasets as training sets, we sought to find
a consistent gene signature that combined with clinical
prognostic factors (age, sex and stage) would model OS
risk. A validation dataset for each NSCLC subtype was
used to confirm the prognostic value of the clinical-
genomic signatures and the improved predictive power
of these models compared with the clinical ones.
Derivation of the clinical-genomic signatures
After the filtering processes (using the correlation and
prognostic filters described in Methods), we selected 513
and 150 candidate genes for ADC and SCC, respectively
(Additional file 2: Table S6 and Additional file 3:
Table S7). In the 513 selected gene set for ADC, the
GO biological processes highly significantly enriched
were related either to cell proliferation or metabolism.
Among the top 15 enriched pathways 13 were related to
these two categories, including “RNA metabolic process”
(GO:0016070; P = 6.40e-22), “M/G1 transition of mitotic
cell cycle” (GO:0000216; P = 1.25e-20), “mRNA metabolic
process” (GO:0016071; P = 1.21e-19), “regulation of cellular
amino acid metabolic process” (GO:0006521; P = 5.75e-18),
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P = 1,69E-16); “cell cycle checkpoint” (GO: 0000075;
P = 4,95E-16), etc. On the other hand, intriguingly, in the
case of SCC, the selected candidate gene set presented
a much smaller number of enriched gene sets and their
relationship with cancer pathways is not as apparent.
In fact, only two pathways were significantly enriched,
which suggest the much higher intrinsic biological het-
erogeneity in the SCC cases analyzed in the previously
published cohorts. The most prominent enriched GO
biological pathways in SCC are: “leukemia inhibitory
factor signaling pathway” (GO:0048861; P = 0.046) and
“morphogenesis of a polarized epithelium” (GO:0001738;
P = 0.046). The complete tables with the enriched gene
sets for both types of cancer, ADC and SCC, are in-
cluded in Additional file 4: Tables S8 and Additional
file 5: Table S9, respectively.
Then, a gene ranking was performed using the multi-
variate Cox regression p-values. The regressors for each
gene were the clinical variables and the number of gene
copies. Then, this gene ranking was modified based on
the NetRank methodology. Finally, several candidate
gene signatures obtained according to the Akaike Informa-
tion Criterion were averaged according to the Akaike
weights. This methodology rendered two clinical-genomic
signatures (see Table 1) containing 7 and 5 prognostic
genes for ADC and SCC, respectively (Detailed calculations
and intermediate results are shown in Additional file 1).
The genes included in the ADC signature were: YES1 and
TYMS (both located at 18p11.32), HMGN1 (21q22.2),
PSMA4 (15q25.1), MYO1E (15q22.2), POFUT2 (21q22.3)
and SLC25A20 (3p21.31) In the SCC signature the genesTable 1 Genes that constitute the 7-gene and 5-gene signature
for ADC and SCC
Signature Gene
name
Cytoband DNA copy numbera
Poor prognosisb Good prognosisb
ADC YES1 18p11.32 0.11 −0.18
TYMS 18p11.32 0.11 −0.19
HMGN1 21q22.2 −0.12 0.11
PSMA4 15q25.1 0.01 −0.23
MYO1E 15q22.2 −0.04 −0.19
POFUT2 21q22.3 −0.13 0.10
SLC25A20 3p21.31 −0.08 −0.27
SCC GPD1L 3p22.3 −0.41 −0.24
TRA2B 3q27.2 0.66 0.72
CTNND1 11q12.1 −0.21 0.07
DICER1 14q32.13 0.13 −0.23
ZNF292 6p14.3 0.04 −0.14
aMean gene copy number data (in log2ratio) are shown for the training set
bPatients with a risk score greater (smaller) than the median are considered
patients with poor (good) prognosisselected through our algorithm were: GPD1L (located at
3p22.3), TRA2B (3q27.2), CTNND1 (11q12.1), DICER1
(14q32.13) and ZNF292 (6p14.3).
In relation to the clinical covariates, our methodology
imposed their directions based on a priori knowledge
[4]. In particular, the risk coefficients for age, sex and
the incremental risk for each of the stages were forced
to be non-negative (i.e., the overall risk was imposed to
increase with age and stage and to be higher in men
than in women). In our analysis, the coefficients for sex
and the incremental risk of stage IIA relative to IB were
null in both clinical-genomic signatures (when the
restriction of the direction was not included, the risk for
these clinical variables had a small negative value -data
not shown-). As a result, both clinical-genomic signatures
included the same predictive clinical factors: age, stage IB
vs IA and stage IIB vs IB (Survival model inference in
Additional file 1).
All genes present in the clinical-genomic ADC and SCC
signatures, except SLC25A20, were significantly associated
with survival (P < 0.05). In particular, YES1 and TYMS
showed the highest predictive power (P < 0.001). The pre-
dictive power of SCC genes was slightly lower than that of
ADC genes. Furthermore, the predictive power of the
stage covariates in the SCC model was not statistically
significant. These could be due to the reduced sample size
of the SCC training set, with only 56 labeled samples,
compared with the 99 ADC labeled samples.
Prognostic evaluation of the clinical-genomic signatures
The prognostic role of the clinical-genomic signatures
was evaluated in the training set. Risk scores were calcu-
lated according to the clinical-genomic signatures and
dichotomized with the medians of the scores (therefore,
in each histological subtype, the low and high risk groups
included the same number of patients). Furthermore, the
prognostic capacity of the signatures was validated in two
independent datasets, one for each histological subtype.
All prognostic significances of both the clinical-genomic
and the clinical models are shown in Table 2 and Figs. 2
and 3. The clinical-genomic signatures outperformed the
clinical signatures in both the training and validation sets,
i.e. the p-values were smaller for the clinical-genomic
models than for the clinical models and a wider separation
of the Kaplan-Meier survival curves was clearly observed.
In order to elucidate whether the differences between
the clinical and the clinical-genomic models were statis-
tically significant, we performed the Harrell’s comparison
test [28], separately for ADC and SCC. This test can be
used to evaluate if a prediction model significantly out-
performs a reference model. The Harrell’s test p-values
were computed between clinical-genomic and clinical or
genetic predictors for both ADC and SCC. Table 3
shows that the clinical-genomic signatures significantly
Table 2 Prognostic evaluation of the clinical-genomic and clinical signatures among the ADC and SCC patients in the corresponding
training and validation sets
Datasets Subtype Type of signature HR (95 % CI) p-value* p-value**
Training sets ADC Clinical-genomic 2.63 (1.95–3.53) 8.377e–11 4.76e–7
Clinical 2.72 (1.62–4.55) 7.064e–5 0.0015
SCC Clinical-genomic 4.06 (2.20–7.46) 3.176e–6 1.87e–5
Clinical 2.72 (1.36–5.45) 0.002 0.029
Validation sets ADC Clinical-genomic 2.1 (1.12–3.93) 0.01 0.008
Clinical 2.09 (0.86–5.06) 0.05 0.06
SCC Clinical-genomic 1.56 (1.10–2.24) 0.007 0.019
Clinical 1.42 (0.89–2.25) 0.07 0.121
*One-tailed p-value using the Cox proportional hazard model
**Log-rank test p-value
Fig. 2 Kaplan Meier curves for the training (a, b) and validation (c, d) sets of ADC patients. For each case, patients were divided into two risk
groups according to the predicted risk using either clinical (a, c) or clinical-genomic data (b, d). Survival curves were compared using log-rank
test p-values
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Fig. 3 Kaplan Meier curves for the training (a, b) and validation (c, d) sets of SCC patients. For each case, patients were divided into two risk
groups according to the predicted risk using either clinical (a, c) or clinical-genomic data (b, d). Survival curves were compared using log-rank
test p-values
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models in both the training and validation sets, except
for the ADC signature in the validation set, which des-
pite having a better performance (p-value below 0.5) did
not reach statistical significance. Nevertheless, compared
to clinical-genomic signatures, the genetic signatures for
both ADC and SCC validation sets (not included in
Table 3) had a worse performance (P = 0.066 for ADC
and P = 0.020 for SCC).Table 3 Statistical comparison between clinical-genomic and
clinical prognostic models. *p-values from the Harrell’s test
Dataset Subtypes p-values*
Training set ADC 1.4601e–10
SCC 3.3228e–09
Validation set ADC 0.134
SCC 0.0005Discussion
In this study, we have developed two clinical-genomic
signatures to predict OS in chemotherapy-naïve, early
stage ADC and SCC lung cancer patients. These signa-
tures were based on the combination of clinical data and
copy number alterations of a limited number of genes,
and were validated in independent series.
To date, most of the published prognostic profiles are
gene expression profiles based on RNA levels [5–7]. In
our view, our prognostic signature based on CNA may
have stronger prospects of clinical utility due to the
higher stability of DNA when compared to RNA. In rela-
tion to other CNA survival predictors in the literature,
most of them only inform about the prognostic value of
individual gene or chomosomal region alterations [14, 15].
In our case, the group of genes selected for our profiles
provides a more precise correlation with outcomes than
individual genes. Moreover, in our selection algorithm, we
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between CNA and gene expression.
One of the challenges for this type of studies is the sam-
ple size required to achieve sufficient statistical robustness.
This is especially a problem when early stage lung cancer
patients are studied, as the numbers of events (disease
progression or cancer-related death) are low. However, the
availability of previously published array data allowed us to
overcome this difficulty, combining DNA copy number
data from other studies. In order to include comparable
tumor samples, we minimized intra-tumor heterogeneity
by performing an in silico tumor purity correction step for
each of the samples, an approach that has been developed
recently [29]. Still, since the number of samples is much
smaller than the number of analyzed genes, a proper selec-
tion of the genes included in the signature is more import-
ant than the algorithm adopted to generate the survival
model. With the aim to ease the feature selection process,
we selected only those genes with prognostic value based
on two external databases, (Prognoscan and GeneSigDB)
and significant correlation between CNA and gene expres-
sion. This comprehensive selection process allowed us to
derive two profiles that included a reduced number of
genes (5 genes for the SCC profile and 7 genes for the
ADC profile). A low number of genes in the final signature
increases the feasibility of the clinical application of these
signatures.
Genomic-based prognostic signatures usually include
only genetic aberrations without taking into account well-
established clinical prognostic features such as age and
stage. Here, we proposed an integrated clinical-genomic
signature. The clinical-genomic profile outperformed both
the clinical-only data (see Figs. 2 and 3) or genetic-only
data (see Additional file 6: Figures S9 and S10).
An additional novelty of our study is the description of
a prognostic profile for SCC lung cancer patients. Most
of the lung cancer prognostic signatures have been pro-
posed for ADC and a prognostic signature for SCC is
still missing. Although copy number and expression pro-
files of SCC lung carcinomas have been extensively
described [10, 30, 31], assigning these patients into
groups of different prognosis is still a challenge [13],
maybe due to the potential existence of several biological
subtypes within the SCC category [13, 32]. In our study
the performance of the clinical-genomic model in SCC
was lower compared to the ADC series, yet the clinical-
genomic approach, was still more predictive compared
to the clinical model.
According to the ADC clinical-genomic profile, patients
with a higher risk of death showed an increase in the copy
number of YES1, TYMS, MYO1E, SLC25A20 and PSMA4,
and a decrease in the copy number of HMGN1 and
POFUT2. YES1 is a non-receptor tyrosine kinase from the
SRC family kinase proteins. Previous studies in differentneoplasms have shown that in vitro knock down of YES1
expression induce cell growth and metastasis reduction
[33]. TYMS has been extensively studied in lung cancer as
a prognostic marker of survival and a predictive marker of
response to pemetrexed [34] and 5-FU. HMGN1 protein
binds to nucleosome and modifies chromatin structure. It
participates in the repairing process of DNA lesions
following UV light exposure and ionizing irradiation. In
addition, HMGN1 controls the transcription process of
some oncogenes and tumor suppressor genes involved in
tumor progression, mainly suppressing the development
of cancer [35]. Expression of PSMA4 is up-regulated in
lung cancer [36]. It has been related to lung cancer pro-
liferation and apoptosis and it is one of the genes located
in the 15q24–25.1 region associated with lung cancer risk
in western populations [37]. MYO1E codes for the class I
myosin, involved in receptor mediated endocytosis [38].
Increased levels of MYO1E mRNA have been associated
with recurrence of hepatocellular carcinoma [39].
POFUT2 is an O-fucosyltransferase responsible for
the O-fucosylation of thrombospondin type 1 and EGF
repeats [40]. There is limited evidence on the role of this
protein in cancer, but results of Pofut2 knockout mice
showed that the loss of the protein leads to epithelial-
mesenchymal transition in mouse embryogenesis, suggest-
ing an important role of the protein in cancer [41]. No
studies have been performed in cancer to investigate copy
number or gene expression alterations of SLC25A20, a
transport protein present in the mitochondrial membrane.
According to the SCC clinical-genomic profile, an
increase in the copy number of ZNF292 and DICER1,
and a decrease in the copy number of TRA2B,GPD1L,
and CTNND1 is an indicator of poor prognosis. The
association found in our study between CNA of GPD1L
and CTNND1 and prognosis is consistent with the asso-
ciations previously described not only in lung cancer but
also in other neoplasms [42, 43]. TRA2B amplification
has been described in several neoplasms, including lung
cancer [44]. Upregulation of Tra2β protein has been as-
sociated with aggressiveness in cervical cancer [45];
however the role of this protein in lung cancer is
unknown. No association between ZNF292 expression
and progression has been described, and contrasting
results have been published regarding the prognostic
value of the DICER1 abnormal expression, depending on
the tumor origin. Whereas low DICER1 expression has
been correlated with worse prognosis in chronic lympho-
cytic leukemia and melanoma [46, 47], high expression
has been correlated with reduced survival in prostate
adenocarcinomas and colorectal carcinomas [48, 49]. In
our clinical-genomic profile, DICER1 gene deletions were
associated with low risk in SCC patients. Previous studies
in lung cancer showed association between low level
expression and poor survival [50] in adenocarcinoma
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together. Further studies are needed to clarify if aberrant
DICER1 expression has a different prognostic role in SCC
and ADC subtypes or to explain the apparently opposite
direction of the prognostic value of DICER1 gene copy
number and the expression of the transcribed protein.
Our prognostic profiles were validated in silico in two
independent series of stage I and II ADC and SCC sam-
ples from TCGA. However, in order to apply these profiles
in the clinic, future validations using routinely available
techniques for CNA analysis, such as FISH or qPCR, as
well as independent prospective cohorts are needed.
Conclusion
In conclusion, based on our novel selection algorithm,
we have designed two prognostic profiles for stage I and
II lung ADC and SCC patients based on both CNA and
clinical features. These combined clinical-genomic pro-
files were able to improve the prognostic classification of
patients based on clinical characteristics. After a pro-
spective validation, this new tool could guide clinical
management in early-stage lung cancer patients.
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